There is a need to assess the safety of foods deriving from genetically modified (GM) crops, including the allergenic potential of novel gene products. Presently, there is no single in vitro or in vivo model that has been validated for the identification or characterization of potential food allergens. In stead, the evaluation focuses on risk factors such as source of the gene (i.e. allergenic vs. non-allergenic sources), physicochemcial and genetic comparisons to known allergens, and exposure assessments. The purpose of this workshop was to gather together researchers working on various strategies for assessing protein allergenicity and 1) to describe the current state of knowledge and progress that has been made in the development and evaluation of appropriate testing strategies and 2) to identify critical issues that must now be addressed. This overview begins with a consideration of the current issues involved in assessing the allergenicity of GM foods. The second section presents information on in vitro models of digestibility, bioinformatics, and risk assessment in the context of clinical prevention and management of food allergy. Data on rodent models are presented in the next two sections. Finally, non-rodent models for assessing protein allergenicity are discussed. Collectively, these studies indicate that significant progress has been made in developing testing strategies. However, further efforts are needed to evaluate and validate the sensitivity, specificity, and reproducibility of many of these assays for determining the allergenicity potential of GM foods.
Introduction and Overview of Food Allergy. G. S. Ladics and W. Dong
The prevalence of food allergy is approximately 1-2% in adults and 6-8% in children (Metcalfe, et al., 1996; Sampson, 1997) . Most food allergies are mediated by antigen specific IgE and are characteristic of type-I reactions. It is such responses that are the focus of this paper (Fig. 1) . Food allergic reactions occur typically in individuals who are genetically predisposed to allergy and who have been previously sensitized to the allergen (Sicherer, 2000) . These reactions can range from effects on one or more of the following systems: gastrointestinal tract (nausea, vomiting, diarrhea); skin (urticaria, dermatitis, angioedema); respiratory tract (rhinitis, asthma, bronchospasm). The potential consequences of food allergy can also be serious, with severe reactions (i.e., anaphylaxis) occurring in approximately 3 individuals per 100,000 per year (Burks and Sampson, 1997) .
Overall, approximately 90 percent of all food allergies are associated with a small number of specific proteins represented by eight major allergens: peanuts, tree nuts, cows' milk, hens' eggs, fish, crustacea (e.g., shrimp), wheat, and soybeans (Metcalfe et al., 1996) . Of the thousands of proteins in food, approximately 200 proteins found among roughly 140 foods or food groups are actually food allergens (Day, 1992; Hefle et al., 1996) . The remaining 10 percent of food allergies are caused by less commonly allergenic proteins or minor allergens and affect a relatively small number of people (Hefle et al. , 1996) . Importantly, food, whether developed by conventional means or through biotechnology, is a potential source of allergens. Nevertheless, there is a concern within the public, government, and industry that food allergens may be moved between foods or that proteins with no history of consumption may be proven to be allergenic when introduced into a food crop using biotechnology. Therefore, it is important that the allergenic potential of biotechnology-derived foods be evaluated. Additional information regarding the safety of genetically modified foods can also be found in a recently published position paper by the Society of Toxicology (Society of Toxicology, 2003) .
Unlike respiratory allergies, such as hay fever, there are no effective treatments for food allergy. Therefore, patients manage food allergy by avoiding the consumption of offending foods. Consequently for biotechnology, allergy assessment has two main goals: 1) what assurances can be made that existing food allergens are not transferred into, or hidden in, new foods, and 2) what assurances can be made concerning the potential of an introduced protein to become a food allergen de novo. It is this second concern that was the focus of this workshop.
The summaries that follow provide an overview of each speaker's presentation.
Allergy Assessment of Biotechnology Products: What Are the Issues Associated with the Use of Animal Models? M.P. Holsapple
In spite of extensive efforts to characterize the mechanisms of allergy at both cellular and molecular levels, we still have only limited understanding of the characteristics that allow a protein to induce a specific IgE response, and that render an individual susceptible to allergenicity. Because of these complexities, it has long been recognized that there is no single parameter that can address allergic potential, and instead, there is a reliance on a "weight of evidence" approach. Historically, the strategy to address allergenicity of biotechnology products has been captured in a "decision tree" (Metcalfe et al., 1996; FAO/WHO, 2001) , that relies on the following parameters: source of the gene; sequence homology; human studies including serum testing; pepsin resistance; the prevalence of the trait (i.e., level of expression of the protein in the plant); and animal models (Fig. 2) . The remainder of this section will focus on animal models by raising some specific questions that must be addressed. * What is the most appropriate design for an animal model? Is a rodent (i.e., mouse or rat) the best choice or should a non-rodent model that can better mimic human clinical signs (i.e., pig or dog) be employed? What kind of dosing regimen should be used (i.e., number and timing of sensitization doses)? Should the dose-response relationship always be determined? Should adjuvant be used? * What is the most appropriate route of exposure? The oral route may be the most relevant for food; but the complication of oral tolerance by prior exposure to the protein must be overcome. Should the potential for exposure via inhalation (i.e., through exposure to pollen or dust from food derived from biotechnology) be considered? Should intraperitoneal (i.p.) injection be considered for sensitization and/or elicitation? An i.p. injection may represent the most direct assessment of the allergic potential for a novel protein, and it has been demonstrated that i.p.
injections may overcome the tolerance that would be manifested if the protein is administered orally. There is no doubt that a validated predictive animal model would help in the hazard identification of biotechnology products. The term, "validation", can be used as a challenging opportunity or an insurmountable hurdle. In that context, it is reasonable to question the state of "validation" for the following parameters: Sequence homology? Serum testing? Pepsin digestibility? It is also reasonable to question if we should expect more from an animal model than we could currently derive from parameters currently used in the "decision tree" in terms of the concordance of results, and the level of predictivity. Astwood, R. E. Goodman, A. Silvanovich, and G.A. Bannon. Recent progress in the understanding of both the natural history of food allergy and the characteristics which define food and other allergens has lead to new insights into the potential predictive value of in vitro tools with a view towards preventing the development of new food allergies. The most advanced of these tools include 1) the adaptation of bioinformatics techniques; and 2) the refinement of two factors which influence protein exposures via foods: stability to digestion and protein levels.
Bioinformatics
Many of the major food and respiratory allergens have been identified and cloned; and today databases (e.g. as located at the website http://www.allergenonline.com) contain many hundreds of protein sequences for allergens. Therefore, it is possible to screen candidate proteins for similarity to known allergens very early in product development, even before plants are transformed, using bioinformatics tools such as FASTA (Pearson and Lipman, 1988) . Proteins that share a high degree of sequence similarity are often homologous and share three-dimensional folds (Pearson, 2000) . Aalberse (2000) has noted that proteins sharing less than 50% identity over their entire length are unlikely to be cross-reactive, and only when they share more than 70% identity does cross-reactivity become common. To illustrate, tropomyosin protein is found in a broad array of animal species, yet allergic reactions are common to only a subset of these proteins. By creating a phylogenetic cluster diagram using the amino acid sequences of tryopomyosin proteins , a clear bifurcation in allergenicity can be distinguished that is consistent with taxonomic considerations (Fig. 3) . However, lack of similarity to exisiting allergens alone is insufficient evidence to conclude lack of potential allergenicity; and bioinformatic data should be evaluated in the context of other information such as overall structural and physicochemical similarity .
There is some concern that the FASTA search might miss short regions within a protein that are identical or highly similar in sequence to an existing allergen and have the potential to bind IgE. IgE-binding epitopes, however, have only been identified for a few allergens. In the absence of a complete description of IgE epitopes for all known allergens, a theoretical database of all potential epitopes for these same allergens can be screened by scanning all overlapping peptides (in this case eight or more amino acids in length) of all the allergens of the database and comparing them in pair-wise fashion to all same-size potential peptides of the test protein using computer software or scanning manually. A recent FAO/WHO scientific panel recommended using a six amino acid window for this type of analysis (FAO/WHO, 2001 ). However, Hileman et al. (2002) showed that an amino acid window size of less than eight resulted in a high rate of false positives. Another consideration is that two IgE binding epitopes on the same molecule are required to cross-link high affinity IgE receptors on mast cells and induce an intracellular signal.
Therefore, a single match in this analysis may or may not be clinically significant.
Digestibility in vitro and Protein Abundance
Proteins that are highly digestible would be expected to have less opportunity to exert adverse health effects when consumed. Standardization of the pepsin digestibility assay conditions (i.e. pepsin concentration, pH, temperature, etc.) has been described in the U.S. Pharmacopia and is sometimes referred to as simulated gastric fluid (SGF). The pepsin assay was not meant to precisely mimic the fate of proteins in in vivo conditions, but rather to evaluate the susceptibility of the protein to digestion under fixed conditions in vitro and provide information that, together with other evidence such as abundance (i.e. exposure), would be useful in predicting whether a dietary protein may become a food allergen.
Stability to digestion in vitro (using pepsin) of the major allergens found in the most common allergenic foods was the first factor to be studied systematically . Under the conditions described in this study, food allergens were more resistant to pepsin hydrolysis than were common plant proteins. However, not all allergens from the most common allergenic foods were stable in the pepsin digestion assay. Stability of the whole protein or fragments from the allergens tested ranged from 8 minutes to 60 minutes whereas stability for the non-allergen plant proteins was 15 seconds. Subsequent studies repeating the pepsin digestion assay on these major food allergens have been performed (Besler et al., 2001) . In general, the original findings that these allergens were stable to pepsin digestion relative to non-allergen proteins were confirmed but the length of time that either the whole protein or fragments of the allergen were stable did not always agree.
These differences may be due to subtle changes in the pepsin digestibility assay or in the method by which the proteins of interest were detected. Indeed, there may be an over-reliance on the use of the pepsin digestibility assay as a single decisive parameter, as the assay is not intended to mimic human digestion processes perfectly and alterations of the conditions of the assay can yield different results (Fu et al, 2002) . ILSI has proposed a standardization process for the assay so that results from different laboratories can be directly compared (ILSI, 2002 ; unpublished data).
Complete food allergens (having the capacity to both sensitize and elicit allergy) have several biochemical characteristics in common including their abundance in the food and the ability to promote IgE production and elicit IgE mediated clinical symptoms (Aalberse, 1997) .
Another significant characteristic of complete food allergens is that they are stable to the proteolytic and acidic conditions of the digestive tract. However, incomplete allergens (having the capacity to elicit allergy, but not sensitize) would not be expected to be stable to pepsin digestion . Pepsin digestion stability is believed to impart on the allergen an increased probability of reaching the intestinal mucosa intact where absorption of significant quantities may lead to sensitization as well as impact the exposure rate of this protein to susceptible populations, an important variable in any risk assessment paradigm. While these are characteristics of most major food allergens, there are exceptions. Patatin (Sol t 1), the major allergen of potato (Seppala et al ., 1999 ) is one notable exception. However, patatin represents >40% of total protein in potato, which equals about 5 grams of patatin per serving. The emerging story is that stability and abundance together appear to be important factors, where stability may be a contributor to overall exposure. In the case of patatin, high exposure is achieved in the absence of digestive stability; and with the effect of sensitization.
Animal Models for the Identification of Protein Allergenic Potential: The BALB/c
Mouse. I. Kimber and R. J. Dearman Research in this Laboratory with respect to food allergy has two main objectives. The first of these is to define the characteristics that confer on proteins the ability to induce allergic sensitization (Huby et al. , 2000) . The second, more pragmatic, objective is to develop a method for assessment of the inherent allergenic potential of proteins that could be used for the purposes of hazard identification and characterization.
Specifically, the aim is to develop an animal model that would provide an holistic evaluation of sensitizing activity, and which could be used in concert with other information to inform the safety assessment process Kimber and Dearman, 2001) . To this end we have chosen to examine immune responses provoked in BALB/c mice; a strain that is predisposed to mounting strong IgE antibody responses. The strategy is to distinguish between allergenic proteins and those that, despite being immunogenic, lack the potential to cause allergic sensitization. In this context overall immunogenicity is measured as a function of the vigor of induced IgG antibody responses (measured by enzyme-linked immunosorbent assay; ELISA), while allergenicity is defined on the basis of IgE antibody production (homologous passive cutaneous anaphylaxis [PCA] assay) ).
Our chosen experimental approach is to administer test proteins to mice using intraperitoneal (ip) injection. Although it might appear more appropriate to use oral exposure for examination of the allergenic potential of food proteins, this is not necessarily the case. Thus, dietary exposure of rodents to proteins is known not to result in robust IgE responses, even to known allergens, probably due to the induction of oral tolerance. Gavage administration may be somewhat better, but (in our experience at least) is less sensitive than ip injection with regard to the production of IgE antibody . Our view currently is that the failure to elicit IgE antibody production under conditions of exposure where immunogenicity is evident (on the basis of IgG responses) may, together with other sources of information, provide some reassurance that the protein lacks a significant potential to provoke allergic sensitization. It must be acknowledged, however, that the induction of IgE antibody production under these circumstances will not necessarily translate into a risk of sensitization when the protein is experienced via dietary exposure. Notwithstanding this consideration, the first imperative is to provide a robust method for hazard identification that can be used in concert with considerations of resistance to proteolysis, structural homology and immunological identity to provide a reliable safety assessment. Our contention on the basis of investigations to date is that systemic exposure of BALB/c strain mice to test proteins represents the most suitable experimental approach if false negative results are to be avoided. 
M. J. Knippels and A. H. Penninks.
For the safety evaluation of genetically engineered crops the potential allergenicity of the newly introduced protein(s) has become an important issue. However, validated animal models to study the allergenicity of food proteins are not available yet. When developing an animal model several aspects like selection of species and strain, route of exposure for sensitization and challenge, as well as the use of adjuvants are important criteria to consider Penninks et al., 2001) . We have developed an oral sensitization protocol in Brown Norway (BN) rats as this is a high-immunoglobulin (particularly IgE) responder rat strain. We believe that for the evaluation of the intrinsic allergenic potential of new proteins oral application is preferred, and that the presence of an adjuvant is to be avoided.
We showed that upon daily intra-gastric administration of 1 mg ovalbumin (OVA) for 42 days, without the use of adjuvants, the animals developed OVA-specific IgG as well as OVA-specific IgE responses as measured by both enzyme-linked immunosorbent assay and homologous passive cutaneous anaphylaxis (PCA) assay (Knippels et al. 1998 a) . Although in general 80% of the animals developed a response, sometimes no detectable OVA-specific IgE responses were induced. This was probably due to pre-exposure of the animals to OVA through their diets, which induced tolerance in the animals. In previous oral sensitization studies with soy proteins we have shown that an important factor that influences the results of oral sensitization studies is unscheduled dietary pre-exposure of test animals or their parental generation to the antigen under investigation (Knippels et al. , 1998b) . In subsequent studies with BN rats the sensitizing potential of hen egg white (HEW) and cows' milk (CM) proteins was examined. Although antigen-specific IgG responses were found upon daily gavage dosing of the animals with different concentrations of HEW or CM, only a limited number of IgE responders was observed as measured by PCA. However, immunoblotting experiments with these rat sera demonstrated the presence of specific IgE antibodies against both HEW-proteins and CM-proteins (Knippels et al. , 2000) . Moreover, both IgG and IgE antibodies present in sera of rats sensitized orally to HEW or CM and in sera of HEWor CM-allergic patients recognized a comparable profile of allergens in these food products. These results indicate that the specific protein recognition of induced antibodies in the BN rat is comparable with that observed in sera from allergic patients (Knippels et al., 2000) . In a more recent study BN rats were sensitized with different doses (0.01-10 mg) of either crude raw peanut extract or roasted peanut extract.
Although no clear differences were observed in the sensitizing potency of crude, raw or roasted peanut extracts as measured by Th2-mediated IgG2a production a marked difference in response was observed following either intra-peritoneal or oral exposure. After oral sensitization, IgG2a antibodies were directed against all three major peanut allergens (Ara h1, Ara h2 and Ara h3), however, following intraperitoneal sensitization IgG2a antibodies were mainly directed towards Ara h 2 and to a lesser extend against Ara h1 and Ara h3.
More recently, the relative allergenicity of selected allergenic and non-allergenic proteins, based on human experience has been investigated in the BN rat. In these studies Ara h 1 purified from peanut, Pen a 1 (tropomyosin) purified from shrimp or beef tropomyosin, and Sol t1 (patatin) purified from potatoes were used. Preliminary results indicated marked differences in the two identical sensitization studies performed with these purified proteins in BN rats. It was found that the rats in the first study had been unexpectedly pre-exposed in the diet to one allergen used for sensitization and to a cross-reacting allergen, and it is assumed that this affected the results. In the second study the oral sensitizing potential decreased in the following order Ara h 1> Pen a 1> Sol t 1, with no sensitization to beef tropomyosin in either study.
In the BN rat food allergy model in addition to oral sensitization, oral challenge reactions were also investigated (Knippels et al. , 1999) . In previously sensitized animals an increased gut permeability was observed after an oral challenge. An oral challenge with OVA did not induce clear systemic effects on.the respiratory system or blood pressure in the majority of animals. However, this low incidence is considered to be in accordance with clinical observations in food allergic patients.
In conclusion, the results obtained to date indicate that the BN rat might be a useful animal model to study the potential oral allergenicity of "novel" food proteins. However, further testing with either whole food, or with additional purified non-, weak-and strong-allergenic proteins are needed to evaluate further this Brown Norway rat model.
Non-Rodent Animal Models for Assessing Protein Allergenicity. R. M. Helm
Among domestic animals that develop allergy, the atopic dog model (1) and the swine peanut allergy model (2) are appropriate animal models that will provide a comprehensive understanding of IgE-mediated disease mechanisms and may predict potential allergenicity of novel proteins. Similar anatomy, physiology and nutritional requirements of these animals combined with gastrointestinal and immune system maturation and enteric absorption of antibody are fundamental features of these animals that make them attractive to gastrointestinal food allergy investigations. Swine have a natural IgE-mediated like disease to parasites, legumes and pollens reminiscent of that in human allergy. In the veterinary literature, the introduction of soybean protein prior to weaning and positive skin tests to Ascaris suum antigen that suggested an immediate type hypersensitivity response to food allergens could be established in young piglets. Helm et al. (2002) demonstrated that young piglets could be sensitized with peanut extract and upon oral challenge with peanut meal, a moderate to severe gastrointestinal food allergy could be established. Peanut -sensitized piglets presented with a physical appearance including whole body or localized rashes, vomiting, and respiratory distress (stridor) within 60-90 minutes followed by diarrhea 18 -24 hours later. Skin tests with peanut-sensitive animals showed positive wheal and flare responses to peanut extract and the two major peanut allergens, Ara h 1 and 2. In the absence of an anti-swine IgE antibody, passive cutaneous anaphylaxis with heatinactivated serum failed to induce a wheal and flare reaction compared to non heat-inactivated serum from peanut-sensitive animals confirming an IgE-mediated response. Histological assessment of tissues from inflamed areas showed evidence of mucosal edema, enlarged goblet cells and extrusion of mucus into the lumen compared to stomach tissues from non-peanut sensitized piglets. The small intestine showed marked edema, mucus secretion, epithelial denudation, and vascular congestion with hemorrhage in piglets responding to peanut challenge.
Cytokine analysis of cell supernatants revealed minor increases in IL-4. IL-10 mRNA was increased in peanut challenged small intestine.
The atopic dog and peanut allergy swine model provide ample opportunity for mechanistic studies of hypersensitivity, investigations into therapeutic strategies, and possibly predicting protein allergenicity. The major concern lies in the large size and husbandry needed for these investigations and the associated cost. Ultimately, these animal models will provide valuable information characterizing the underlying mechanisms of food allergy, immunopathogenic studies and therapeutic intervention studies that should translate well to human food allergy disease.
Workshop Summary
Advances in the science of allergy assessment for foods and feeds derived from biotechnology derived crops include the availability of expanded and robust databases of known allergen sequences, refinements in bioinformatics criteria and multi-center validation of in vitro digestibility assays such as the pepsin assay. As the needs for a more comprehensive risk assessment become apparent, appropriate public policy measures will likely include an evaluation of threshold doses and the need for a better understanding of how much allergen is too much (Taylor et al., 2002) . Several animal models are also currently under development in both rodent and non-rodent species, that evaluate different endpoints, routes of exposure, and dosing regimens. Significant progress has been made in developing testing strategies to assess the allergenic potential of proteins, however, further efforts are needed to evaluate and validate the sensitivity, specificity, and reproducibility of many of these assays Clinical signs upon oral challenge (i.e., increase in permeability of the gastrointestinal tract, decrease in breathing frequency, decrease in blood pressure).
Relatively long dosing time needed for sensitization
Relative allergenicity of tested food proteins fits human situation
To obtain naive animals for the sensitization studies, the BN rats need to be bred and raised for at least two generations on a diet free from the protein(s) under investigation.
Induced IgE antibodies are directed against the same proteins as compared to the IgE antibodies present in food allergic patients 
